The immune system is meant to protect the body from infection and disease. But with age, it can become less capable of doing so. However, Mayo Clinic researchers have found that some older people ...
Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...
Healio spoke with Micaela F. Bayard, MD, a rheumatologist at Mount Sinai and assistant professor of rheumatology at The Icahn School of Medicine, about the treatment landscape in giant cell arteritis.
SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...
Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...
(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease that ...
For most of us, the phrase "stroke of the eye" sounds like a metaphor. But for UK HealthCare's Jagannadha "Jay" Avasarala, M.D., Ph.D., it's a literal and urgent diagnosis—one that could mean the ...
Please provide your email address to receive an email when new articles are posted on . At the Congress on Controversies in Ophthalmology, Lee and Susan Mollan, MBChB, FRCOphth, PhD, debated this ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the ...
A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...
Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...
Ultrasound (US) is a very helpful clinical tool in rheumatology due to its low cost, portability, and accessibility for point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results